Gene Expression and Microarray Investigation of Dendrobium Mixture as Progressive Therapy for the Treatment of Type 2 Diabetes Mellitus

被引:8
|
作者
Xu, Qian [1 ]
Liu, Yun [1 ]
Cong, Yi-Bo [2 ]
Zheng, Yuan-Yan [1 ]
Zhang, Jie-Ping [1 ]
Cui, Yi [3 ]
Shi, Hong [1 ]
机构
[1] Fujian Univ Tradit Chinese Med, Inst Integrated Chinese & Western Med, Fuzhou, Peoples R China
[2] Fujian Univ Tradit Chinese Med, Coll Nursing, Fuzhou, Peoples R China
[3] Fujian Med Univ, Inst Biomed, Fuzhou, Peoples R China
关键词
Diabetes; Gene expression; Dendrobium mixture; Microarray testing; FXYD3;
D O I
10.4314/tjpr.v12i2.10
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose: To examine the gene expression profile, as well as blood sugar-lowering and lipid-lowering molecular mechanisms of Dendrobium mixtures in a diabetic rat model. Methods: Sprague Dawley (SD) rats were fed high-fat/high-glucose for 16 months. Those with random blood glucose > 16.7 mmol/L were used as the model group and treated with Dendrobium mixture (DEN, containing Dendrobium, Astragalus, Schisandra, etc) in clinically equivalent dose (12 g/kg). The liver RNA of the rats in all three groups (control, model and DEN) was used for Agilent genome expression microarray testing and subsequent data analysis. Result: Between the diabetic rat group and the wild-type group, 1339 functional genes showed differences in expression levels (p < 0.05). After Dendrobium treatment, only 380 genes showed differences in expression (p < 0.05). The expression level of nearly 1000 genes returned to normal after drug treatment (compared with the wild-type group, p > 0.05). Genes whose expression normalized were mainly those affected by the disease state and associated with glucose and lipid metabolism, cell growth, apoptosis, biosynthesis, olfactory receptors, or cytoskeletal proteins. Conclusion: Progressive therapy with Dendrobium mixture, which has glucose- and lipid-lowering effects, is associated with multi-gene expression pathways. By treating diabetic r and wild-type rats with the mixture, the disorder is further understood at the transcriptomic level.
引用
收藏
页码:195 / 201
页数:7
相关论文
共 50 条
  • [31] Bioinformatics analysis of hepatic gene expression profiles in type 2 diabetes mellitus
    Chen, Zhe
    Yuan, Weiqu
    Liu, Tao
    Huang, Danping
    Xiang, Lei
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2019, 18 (06) : 4303 - 4312
  • [32] Candidate Gene Expression in Adult Zebrafish Models of Type 2 Diabetes Mellitus
    Shezi, Mlondi
    Snyman, Celia
    Niesler, Carola Ulrike
    ZEBRAFISH, 2024, 21 (06) : 401 - 408
  • [33] Therapie des Diabetes mellitus Typ 2 Therapy of diabetes mellitus type 2
    S. Wiegand
    Monatsschrift Kinderheilkunde, 2005, 153 : 936 - 944
  • [34] The treatment of type 1 diabetes mellitus with agents approved for type 2 diabetes mellitus
    Munir, Kashif M.
    Davis, Stephen N.
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (15) : 2331 - 2341
  • [35] Pharmacologic therapy for type 2 diabetes mellitus
    DeFronzo, RA
    ANNALS OF INTERNAL MEDICINE, 1999, 131 (04) : 281 - 303
  • [36] Nateglinide therapy for type 2 diabetes mellitus
    Levien, TL
    Baker, DE
    Campbell, RK
    White, JR
    ANNALS OF PHARMACOTHERAPY, 2001, 35 (11) : 1426 - 1434
  • [37] Incretin therapy for diabetes mellitus type 2
    Holst, Jens Juul
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2020, 27 (01) : 2 - 10
  • [38] Insulin Therapy in Type 2 Diabetes Mellitus
    Leahy, Jack L.
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2012, 41 (01) : 119 - +
  • [39] Insulin Therapy for Type 2 Diabetes Mellitus
    Wallia, Amisha
    Molitch, Mark E.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 311 (22): : 2315 - 2325
  • [40] Treatment of insulin resistance in obesity-associated type 2 diabetes mellitus through adiponectin gene therapy
    Banerjee, Amrita
    Sharma, Divya
    Trivedi, Riddhi
    Singh, Jagdish
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2020, 583